Recent Innovations in Collagen Corneal Cross-linking; a Mini Review
Iraklis Vastardis1, *, Brigitte Pajic-Eggspuehler1, Charis Nichorlis1, Jörg Mueller1, 2, Bojan Pajic1, 2, 3
Identifiers and Pagination:Year: 2017
Issue: Suppl-1, M6
First Page: 217
Last Page: 224
Publisher ID: TOOPHTJ-11-217
Article History:Received Date: 04/02/2017
Revision Received Date: 13/03/2017
Acceptance Date: 14/06/2017
Electronic publication date: 31/07/2017
Collection year: 2017
open-access license: This is an open access article distributed under the terms of the Creative Commons Attribution 4.0 International Public License (CC-BY 4.0), a copy of which is available at: https://creativecommons.org/licenses/by/4.0/legalcode. This license permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
The introduction of corneal cross-linking (CXL) with ultraviolet-A (UVA) and Riboflavin photosensitizer (Vit B2) from Seiler et al., revolutionized the treatment of Keratoconus and other corneal ectatic diseases.
Today, the commonly known epithelium off Dresden protocol is in clinical use for the last 15 years with great success and regarded by many as the golden standard.
With several studies demonstrating its simplicity, efficacy and safety this revolutionary method, paved the way for new therapies and strategies in the treatment of corneal ectatic diseases and changed our understanding in corneal biomechanics. Recent scientific and technological advances enabled the creation of various modifications of the initial CXL protocol and the formation of new ones.
This work highlights the recent advances of CXL, such as the role of oxygen, higher fluence and shorter irradiation times as well as the various clinical applications and updates of this method.